Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Randomized Open-label Phase 1b Study of Doxorubicin-based Chemotherapy Regimens, With and Without Sildenafil, With Exploratory Analysis of Intermediate Cardiac Markers
Sponsor: Virginia Commonwealth University
A PHASE1 clinical study on Breast Cancer and Gastrointestinal Cancer, this trial is completed. The trial is conducted by Virginia Commonwealth University and has accumulated 12 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Nov 2018 — Aug 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Virginia Commonwealth University
For direct contact, visit the study record on ClinicalTrials.gov .